Floatz logo

Eptinezumab

Migraine Without Aura

University of Florencemonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Migraine Without Aura cohort.

Asset / SponsorPhaseRating
Topamax
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 4BBB
Dihydroergotamine mesylate
Satsuma Pharmaceuticals, Inc.
Phase 3BBB
PROPRANOLOL
Norwegian University of Science and Technology
Phase 3BB
METOCLOPRAMIDE
Assistance Publique - Hôpitaux de Paris
Phase 4BB
Rimegepant
University of South Florida
Phase 4BB

View all 50 →

Same molecule, other indications

Eptinezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
79 / 100
View asset →
Medication Overuse HeadacheDormant
BBB
Indicative ·
78 / 100
View asset →
Migraine Associated VertigoDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →